Sysmex CZ & SK
Menu

ONCOBEAM CRC RAS KIT

Go beyond KRAS – The All‐RAS‐Panel

Our understanding of the important RAS mutations in CRC has evolved over time. In 2008, KRAS mutations in Codons12 and 13 were the only mutations considered important in determining the appropriate therapy for metastatic colorectal cancer patients. Since that time, recent clinical studies have shown that the detection of additional mutations in KRAS and NRAS codons should also be considered in determining patient eligibility for targeted anti‐EGFR therapies.

A meta‐analysis of randomized, controlled trials (RCT) was conducted on the prevalence of RAS mutations in mCRC. Nine RCTs comprising a total of almost 6,000 participants were evaluated for both KRAS Exon 2 and new KRAS and NRAS mutations. The conclusion of the analysis is that patients with tumors exhibiting one of the new RAS mutations are unlikely to significantly benefit from anti‐EGFR therapy in mCRC. 
In 2015, guidelines were updated to recommend expanded RAS testing prior to use of an anti‐EGFR treatment4‐6. The inclusion of low frequency KRAS and NRAS mutations in Exons 2, 3 and 4 formed the basis for our comprehensive OncoBEAM RAS CRC kit (RUO).

Kontaktujte nás
You have a question and would like to get in touch with our experts? We look forward to receiving your enquiry.

Sysmex CZ s.r.o.

Plynárenská 499/1

602 00 Brno

+420 548 216 855

+420 548 216 343

Sysmex Slovakia s.r.o.

Trenčianská 47

821 09 Bratislava

+421 2 6453 2881-2

+421 2 6428 1651

Copyright © Sysmex Europe SE. All rights reserved.